Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06574347
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-25
Brief Title:
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRmMET Locally Advanced or Metastatic NSCLC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase II Study of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRmMET Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRmMET Locally Advanced or Metastatic NSCLC
Detailed Description:
A MulticenterRandomizedopen-labelPhase II Study to Evaluate the Efficacy and Safety of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients with EGFRmexon 19 deletion or exon 21 L858RMET Locally Advanced or Metastatic Non-small Cell Lung Cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None